ESMO 2022 | Assessment of short preoperative endocrine therapy in the ADAPT and ADAPTcycle trials

The Phase II/III ADAPT trial (NCT01779206) has previously revealed Ki67 and recurrence score in baseline core biopsy as promising biomarkers to optimize adjuvant therapy in luminal early breast cancer. Nadia Harbeck, MD, PhD, Ludwig Maximilians University, Munich, Germany, gives a comparison of data from the ADAPT trial and the ADAPTcycle trial (2018-003749-40), which assessed ribociclib versus chemotherapy in HR+/HER2- early breast cancer. Both trials recorded similar robust responses in post-menopausal women and outcomes were additionally improved for pre-menopausal women in the ADAPTcycle with the addition of GnRH agonists. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.